Results 121 to 130 of about 33,585,029 (332)
Treatment of Fractured Femur at the Site of the Casualty [PDF]
F. B. Chavasse
openalex +1 more source
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez+17 more
wiley +1 more source
Cystic Medial Necrosis as a Cause of Localized Aortic Aneurysms Amenable to Surgical Treatment
Henry T. Bahnson, Arthur R. Nelson
openalex +2 more sources
Randomized assessment of rapid endovascular treatment of ischemic stroke.
M. Goyal+43 more
semanticscholar +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
CLINICAL LECTURE ON THE TREATMENT OF DIFFERENT FORMS OF BRIGHT'S DISEASE OF THE KIDNEYS. [PDF]
J. M. DA COSTA
openalex +1 more source
Pembrolizumab for the treatment of non-small-cell lung cancer.
E. Garon+26 more
semanticscholar +1 more source
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen+12 more
wiley +1 more source